Treatment of SARS-CoV-2 pneumonia with favipiravir: early results from the Ege University cohort, Turkey

Hüseyin Aytaç Erdem Pervin Ekren Korkma Derya Çağlayan Meltem Işıkgöz Taşbakan Tansu Yamazhan Mehmet Sezai Taşbakan Abdullah Sayiner Gökengin Deniz

Published in: Turkish journal of medical sciences (2021)

This study provides relevant information for the treatment of COVID-19, suggesting that favipiravir was associated with significant clinical and laboratory improvements in the majority of the patients, is a safe drug with no serious side effects and would merit further investigation.

Keyphrases

sars cov
end stage renal disease
coronavirus disease
chronic kidney disease
ejection fraction
respiratory syndrome coronavirus
emergency department
prognostic factors
replacement therapy
smoking cessation
acute respiratory distress syndrome
respiratory failure